Synonym
Miristalkonium chloride; HSDB5627; HSDB-5627; HSDB 5627
IUPAC/Chemical Name
N-benzyl-N,N-dimethyltetradecan-1-aminium chloride
InChi Key
OCBHHZMJRVXXQK-UHFFFAOYSA-M
InChi Code
InChI=1S/C23H42N.ClH/c1-4-5-6-7-8-9-10-11-12-13-14-18-21-24(2,3)22-23-19-16-15-17-20-23;/h15-17,19-20H,4-14,18,21-22H2,1-3H3;1H/q+1;/p-1
SMILES Code
CCCCCCCCCCCCCC[N+](C)(Cc1ccccc1)C.[Cl-]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Miristalkonium chloride is a biochemical.
In vitro activity:
Herein, the incorporation of the cationic miristalkonium chloride (MKC) surfactant to RGD nanovesicles is explored, comparing two different nanosystems-quatsomes and hybrid liposomes. In both systems, the positive surface charge introduced by MKC promotes electrostatic interactions between the enzyme and the nanovesicles, improving the loading capacity and colloidal stability. The presence of high MKC content in quatsomes practically abolishes GLA enzymatic activity, while low concentrations of the surfactant in hybrid liposomes stabilize the enzyme without compromising its activity.
Reference: ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7825-7838. https://pubmed.ncbi.nlm.nih.gov/33583172/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
368.05
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Tomsen-Melero J, Passemard S, García-Aranda N, Díaz-Riascos ZV, González-Rioja R, Nedergaard Pedersen J, Lyngsø J, Merlo-Mas J, Cristóbal-Lecina E, Corchero JL, Pulido D, Cámara-Sánchez P, Portnaya I, Ionita I, Schwartz S Jr, Veciana J, Sala S, Royo M, Córdoba A, Danino D, Pedersen JS, González-Mira E, Abasolo I, Ventosa N. Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment. ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7825-7838. doi: 10.1021/acsami.0c16871. Epub 2021 Feb 14. PMID: 33583172.
In vitro protocol:
Tomsen-Melero J, Passemard S, García-Aranda N, Díaz-Riascos ZV, González-Rioja R, Nedergaard Pedersen J, Lyngsø J, Merlo-Mas J, Cristóbal-Lecina E, Corchero JL, Pulido D, Cámara-Sánchez P, Portnaya I, Ionita I, Schwartz S Jr, Veciana J, Sala S, Royo M, Córdoba A, Danino D, Pedersen JS, González-Mira E, Abasolo I, Ventosa N. Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment. ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7825-7838. doi: 10.1021/acsami.0c16871. Epub 2021 Feb 14. PMID: 33583172.
1: Tomsen-Melero J, Passemard S, García-Aranda N, Díaz-Riascos ZV, González- Rioja R, Nedergaard Pedersen J, Lyngsø J, Merlo-Mas J, Cristóbal-Lecina E, Corchero JL, Pulido D, Cámara-Sánchez P, Portnaya I, Ionita I, Schwartz S Jr, Veciana J, Sala S, Royo M, Córdoba A, Danino D, Pedersen JS, González-Mira E, Abasolo I, Ventosa N. Impact of Chemical Composition on the Nanostructure and Biological Activity of α-Galactosidase-Loaded Nanovesicles for Fabry Disease Treatment. ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7825-7838. doi: 10.1021/acsami.0c16871. Epub 2021 Feb 14. PMID: 33583172.
